Exagen Inc (XGN)

Jan 12, 2025, 12:00 PM EST - 5 days ago

Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results

Dec 12, 2024, 9:00 AM EST - 5 weeks ago

Exagen Inc. Achieves Key Milestone with 1,000,000th Patient Tested by AVISE® CTD

Nov 14, 2024, 4:30 PM EST - 2 months ago

Exagen Inc. Completes Validation and Regulatory Submission for New Lupus and Rheumatoid Arthritis Biomarkers on the AVISE® CTD Platform

Nov 12, 2024, 1:09 PM EST - 2 months ago

Exagen, Inc. (XGN) Q3 2024 Earnings Call Transcript

Oct 21, 2024, 4:05 PM EDT - 3 months ago

Exagen Announces Acceptance of Five Abstracts at 2024 American College of Rheumatology Convergence

Sep 4, 2024, 4:05 PM EDT - 4 months ago

Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference

Aug 5, 2024, 10:49 AM EDT - 5 months ago

Exagen, Inc. (XGN) Q2 2024 Earnings Call Transcript

Aug 2, 2024, 9:00 AM EDT - 6 months ago

Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 1, 2024, 9:00 AM EDT - 6 months ago

Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

Jul 22, 2024, 9:00 AM EDT - 6 months ago

Exagen to Announce Second Quarter 2024 Results on August 5, 2024

Jun 10, 2024, 1:14 PM EDT - 7 months ago

Time to Play 5 Top-Ranked Stocks With Rising P/E?

AMC APDN HCAT YOU

May 13, 2024, 11:25 AM EDT - 8 months ago

Exagen, Inc. (XGN) Q1 2024 Earnings Call Transcript

May 13, 2024, 8:00 AM EDT - 8 months ago

Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year

Apr 30, 2024, 4:05 PM EDT - 9 months ago

Exagen to Announce First Quarter 2024 Results on May 13, 2024

Apr 26, 2024, 8:30 AM EDT - 9 months ago

Exagen Inc. Announces Changes to the Board of Directors

Mar 18, 2024, 1:23 PM EDT - 10 months ago

Exagen Inc. (XGN) Q4 2023 Earnings Call Transcript

Mar 18, 2024, 8:00 AM EDT - 10 months ago

Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results

Mar 8, 2024, 9:00 AM EST - 11 months ago

Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

Mar 7, 2024, 4:05 PM EST - 11 months ago

Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024

Jan 7, 2024, 12:00 PM EST - 1 year ago

Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance

Nov 20, 2023, 8:37 AM EST - 1 year ago

Exagen Inc. (XGN) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 4:05 PM EST - 1 year ago

Exagen Inc. Reports Strong Third Quarter 2023 Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers

Oct 30, 2023, 4:05 PM EDT - 1 year ago

Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023

Sep 28, 2023, 4:05 PM EDT - 1 year ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2023 Annual Meeting

Sep 12, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference

Aug 7, 2023, 1:42 PM EDT - 1 year ago

Exagen Inc. (XGN) Q2 2023 Earnings Call Transcript

Aug 7, 2023, 8:00 AM EDT - 1 year ago

Exagen Inc. Reports Strong Second Quarter 2023 Results

Jul 26, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Jul 25, 2023, 4:05 PM EDT - 1 year ago

Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023

Jul 24, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. Appoints Paul Kim to Board of Directors

May 30, 2023, 9:00 AM EDT - 1 year ago

Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference

May 15, 2023, 10:23 PM EDT - 1 year ago

Exagen Inc. (XGN) Q1 2023 Earnings Call Transcript

May 15, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. Reports First Quarter 2023 Results

Mar 20, 2023, 7:53 PM EDT - 1 year ago

Exagen Inc. (XGN) Q4 2022 Earnings Call Transcript

Mar 20, 2023, 4:05 PM EDT - 1 year ago

Exagen Inc. Reports Fourth Quarter and Full Year 2022 Results

Feb 27, 2023, 9:00 AM EST - 2 years ago

Exagen Inc. to Participate in Upcoming March Conferences

Jan 30, 2023, 4:05 PM EST - 2 years ago

Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Jan 23, 2023, 9:00 AM EST - 2 years ago

Exagen Inc. Elects Tina S. Nova, Ph.D.

Nov 14, 2022, 10:25 PM EST - 2 years ago

Exagen Inc. (XGN) CEO John Aballi on Q3 2022 Results - Earnings Call Transcript

Oct 31, 2022, 4:05 PM EDT - 2 years ago

Exagen to Announce Third Quarter 2022 Financial Results on November 14, 2022

Oct 17, 2022, 9:00 AM EDT - 2 years ago

Exagen Announces Appointment of John Aballi as CEO

Oct 4, 2022, 8:25 AM EDT - 2 years ago

Exagen Announces Appointment of Andrew L. Concoff MD, FACR, CAQSM, as Chief Innovation Officer

Sep 20, 2022, 4:05 PM EDT - 2 years ago

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

Sep 1, 2022, 4:05 PM EDT - 2 years ago

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Aug 6, 2022, 1:08 PM EDT - 2 years ago

Exagen Inc. (XGN) CEO Ron Rocca on Q2 2022 Results - Earnings Call Transcript

Aug 4, 2022, 4:06 PM EDT - 2 years ago

Exagen Initiates Study to Predict Rheumatoid Arthritis Drug Response (RADR) in Patients with RA

Jul 25, 2022, 4:05 PM EDT - 2 years ago

Exagen Inc. to Participate in the Canaccord Genuity 42nd Annual Growth Conference

Jul 21, 2022, 4:05 PM EDT - 2 years ago

Exagen to Announce Second Quarter 2022 Financial Results on August 4, 2022

Jul 5, 2022, 8:25 AM EDT - 2 years ago

Exagen Releases Largest Comparative Utility Study in Lupus Diagnostics Confirming AVISE® Lupus Delivers Unparalleled Utility